期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

心力衰竭的药物治疗进展 被引量：8

Progress in Drug Therapy for Heart Failure
下载PDF
导出
摘要 近十年,心力衰竭药物治疗取得了突飞猛进的发展,神经内分泌拮抗剂和新型变性肌力药物的陆续出现,已经结束的和正在进行的临床试验表明有一部分药物能更好的改善部分心力衰竭患者的临床症状和预后。现就心力衰竭的药物治疗进展作一综述。 The development of treatments for heart failure has progressed rapidly in the past 10 years. Treatments include both drug therapy and non-drug therapy. Clinical research indicates that some drugs could better improve some of the patients＇ clinical symptoms and their prognosis. This article will review progress made in drug therapy for the treatment of heart failure.
作者 孟培娜 严激
机构地区 安徽医科大学附属省立医院心内科安徽省心血管病研究所
出处 《心血管病学进展》 CAS 2009年第2期334-337,共4页 Advances in Cardiovascular Diseases
关键词 心力衰竭 药物治疗 heart failure drug therapy
分类号 R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献12

  • 1Hjalmarson A,Goldstein S, Fagerberg B, et at. Effect of controller-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure:the Metoprolol CR/XL randomized intervention trial in congestive heart failure(MERIT-HF) [ J]. JAMA ,2000,283 : 1295-1302.
  • 2张奇,沈卫峰,卡维地洛和美托洛尔治疗急性心肌梗死研究协作组.卡维地洛和美托洛尔治疗急性心肌梗死伴心功能不全的对比研究[J].国际心血管病杂志,2006,33(1):52-55. 被引量：15
  • 3Willenheimer R,van Veldhuisen DJ,Silke B ,et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril,as compared with the opposite sequence:results of the randomized cardiac insufficiency Bisoprolol study (CIBIS) Ⅲ [ J ]. Circulation, 2005,112 : 2426-2435.
  • 4Recio-Mayoral A, Kaski JC, McMurray JJ, et al. Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007 : PROSTECT, EVEREST,ARISE,ALOFT, FINESSE, Prageu-8, CARESS in M1 and ACUITY [ J]. Cardiovasc Drugs Ther,2007,21:459-465.
  • 5Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesantan in heart failure: assessment of reduction on mortality and morbidity (CHARM) program[ J]. Am Heart J,2006,152:86-92.
  • 6Baliga RR, Ranganna P, Pitt B, et al. Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms : a retrospective analysis [ J ]. J Card Fail, 2006,12:250-252.
  • 7Cleland JG, Coletta AP, Abdellah AT, et al. Clinical trials update from Heart Rhythm 2007 and Heart Failure 2007: CARISMA, PREPARE, DAVID Ⅱ, SAVE-PACE, PROTECT and AREA-IN-CHF [ J ]. Eur J Heart Fail, 2007,9 : 850-853.
  • 8Fonarow GC. Randomized clinical outcome trials of statins in heart failure [ J ]. Heart Fail Clin,2008,4:225-229.
  • 9Coletta AP, Tin L, Loh PH, et al. Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin affa, FERRIC-HF and KW-3902 [ J ]. Eur J Heart Fail,2006,8 : 105-110.
  • 10Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure : outcome study with Tolvaptan (EVEREST) [ J]. J Card Fail,2005,11:260-269.

二级参考文献15

  • 1[1]Flather MD,Yusuf S,Kober L,et al.Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction:a systematic overview of data from individual patients[J].Lancet,2000,355(9215):1575-1581.
  • 2[2]Dargie H.Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomized trial[J].Lancet,2001,357(9266):1385-1390.
  • 3[3]Dargie HJ.Design and methodology of the CAPRICORN trial:a randomized double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction[J].Eur J Heart Fail,2000,2(3):325-332.
  • 4[4]Hunt SA.ACC/AHA task force on practice guideline.ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult[J].J Am Coll Cardiol,2005,46(6):e1-e82.
  • 5[5]Frishman WH.Carvedilol[J].N Engl J Med,1998,339(24):1759-1765.
  • 6[6]Weber K,Bohmeke T,Van der Does R,et al.Hemodynamic differences between metoprolol and carvedilol in hypertensive patients[J].Am J Hypertens,1998,11(5):614-617.
  • 7[7]Hauf-Zacharion U,Blackwood R A,Gunawardena K A,et al.Carvedilol versus verapamil in chronic stable angina:a multicenter trial[J].Eur J Clin Pharmacol,1997,52(2):92-100.
  • 8[8]Brunner M,Faber T,Greve B,et al.Usefulness of carvedilol in unstable angina pectoris[J].Am J Cardilol,2000,85(10):1173-1178.
  • 9[9]Packer M,Bristow MR,Cohn JN,et al.The effect of Carvedilol on mortality in patients with chronic heart failure[J].N Engl J Med,1996,334(21):1349-1355.
  • 10[10]Packer M,Fowler MB,Roecker EB,et al.Effect of carbedilol on the morbidity of patients with severe chronic heart failure:results of the carvedilol prospective randomized cumulative survival(COPERNICUS) study[J].Circulation,2002,106(17):2194-2199.

共引文献14

同被引文献42

引证文献8

二级引证文献55

心血管病学进展
2009年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部